EGFR and cancer: Sequestration of growth factors by D3 allows erlotinib to be effective at therapeutic serum concentrations in Hep3B cells, which possess wild-type EGFR, reducing the IC50 values from 4.4 uM to 0.2 uM, so D3 addition may broaden erlotinib therapy in non-mutated EGFR cancers.